Introduction
In cases of acute-on-chronic liver failure, liver dialysis, specifically the molecular adsorbent recirculating system (MARS) has been used to bridge patients to liver transplantation and is known to improve outcomes of liver transplantation. 1, 2 MARS therapy consists of filtering blood through a specialized albumin-containing dialysate to remove protein-bound toxins. Blood is filtered in-line through a charcoal column and an anion exchanger column before return. This system allows for the removal of molecules such as bile acids, bilirubin, and cytokines, as well as water-soluble toxins such as creatinine and ammonia. 3 By removing both protein-bound and water-soluble toxins, MARS facilitates liver recovery and also may prevent further deterioration of other organ systems. 4 Overall ECMO mortality is reported to be 47%-61%, 5 and one of the primary causes of death for extracorporeal membrane oxygenation (ECMO) patients is refractory multiple-organ failure including acute liver failure. Acute liver failure (ALF) occurs in ~13-19% of the ECMO population. 6 In our institution, we expanded the indication for MARS to another patient population -cardiopulmonary failure patients requiring ECMO who have developed acute liver failure. This retrospective study was performed to evaluate the questions: can MARS improve acute liver failure on ECMO safely, and to evaluate the survival of the patients with or without MARS treatments on ECMO.
Methods
After approval from the institutional review board, medical records of consecutive ECMO patients between August 2010 and March 2015 were retrospectively reviewed to identify the incidence of liver dysfunction while on ECMO. The only exclusion criterion was any ECMO patient in whom treatment was deemed futile within the first 24 hours of cannulation. Veno-arterial ECMO (VA ECMO) was primarily used for refractory cardiac failure, 7 and veno-veno ECMO (VV ECMO) was primarily used for refractory respiratory failure, 8 detailed in the previous publications.
Among the 133 ECMO patients during the study period, 28 patients (21%) were found to have acute liver failure, defined as total bilirubin ≥ 10 mg/dl or alanine aminotransferase (ALT) ≥ 1000 IU/L.
Further details for inclusion data are shown in Table 1 . These patients were included if they met the criteria for liver failure despite correction of an underlying process such as hemolysis or obstructive cholangitis. The rounding attending physician made the decision for the initiation of MARS. Of the 28 studied patients, 14 patients (Group M) underwent liver dialysis using MARS (Gambro, Lakewood, CO, USA), and 14 patients (Group C) were supported with optimal medical therapies. Medical therapies for Group C and Group M included maintenance of appropriate ECMO flow (body surface area x 2.2 L/min or above), lactulose treatment, nutrition support (via either enteral tube feeding or total parenteral nutrition), and avoidance of hepatotoxic medications, including statins and Amiodarone. In Group M, the MARS system was run with blood flow rates between 100 -150 ml/min using a standard dual lumen dialysis catheter placed in the femoral vein, using a 25% albumin dialysate. 
Results
There were 14 patients in Group M and 14 patients in Group C. Baseline characteristics, pre-ECMO clinical risk factors, and laboratory data were compared and were similar between the two groups ( Table 2 ). Group C and Group M both include patients from overlapping timeframes -Group C was not from an era prior to availability of MARS therapy.
The laboratory values for the patients at the time criteria of acute liver failure were met are shown in Table 3 . MARS therapy was initiated in mean of 5 ± 4 days after ECMO was started in Group M.
The length of ECMO before the patients met the criteria for acute liver failure in Group C was 7 ± 6 days.
The average length of MARS on ECMO was 8 ± 9 days (range 1 -32 days). After 3 days, total bilirubin average for Group M (n=12) decreased by 5.1 ± 12 mg/dL, while Group C (n=9) average total bilirubin increased 2.6 ± 9 mg/dl (p = 0.11). By day 7, the average total bilirubin for Group M (n=11) had decreased by 7.9 ± 15 mg/dL, while in the same time period the average bilirubin for Group C had increased by 7. Bleeding complications while on ECMO, defined as bleeding that required invasive intervention, were 79% (n=11) in both groups. The most common etiologies were gastrointestinal bleeding, epistaxis, and cannula site bleeding; this breakdown was consistent across both groups. Incidence of disseminated intravascular coagulopathy (DIC) was 14% (n=2) for Group M vs. 21% (n=3) for Group C (p = 0.62).
The causes of DIC were multifactorial, and did not appear to be related to MARS treatment. There was no MARS-related sepsis. There were no mechanical ECMO complications, such as flow competition, during MARS.
Survival to wean from ECMO was 64% (9/14) in Group M and 21% (3/14) in Group C, p=0.02
( Figure 3 ). Death related to worsening liver dysfunction was 40% (2/5 deaths) in Group M and 100%
(11/11 deaths) in Group C (p=0.004). Of the patients to survive to wean off of ECMO, only 2 patients (22%) in Group M continued MARS treatment and in both of those cases, liver function was eventually normalized. Five patients (56%) in Group M weaned to a permanent mechanical circulatory support device, versus only 1 patient (33%) in Group C (p=0.06). Thirty days survival after ECMO decannulation was 43% (6/14) in Group M and 14% (2/14) in Group C, p=0.09 ( Figure 3 ). The patients in Group M who survived to wean off of ECMO all recovered liver function, therefore liver failure was not a contributing factor to their death.
Discussion
The research on MARS for patients with cardiopulmonary failure requiring ECMO is very sparse. While we were able to show that survival was improved in Group M versus Group C, it is equally important to note that complications from using the treatment did not arise. In the two cases of DIC within the treatment group, the causes were multifactorial, and did not appear to be related to MARS.
One of the patients was an acetaminophen overdose who was never stabilized following cardiac arrest and ECMO, while the other was due to possible hemolysis after a prolonged course on ECMO requiring three different mechanical circulatory support devices. Complications occurring in the ICU course for both groups were similar, and specifically, incidence of DIC was similar, with no indication MARS was the cause of any case of DIC.
In another study, Rittler 11 reviewed 5 patients after Whipple's operation or liver transplantation complicated with liver failure and gram-negative sepsis and/or fungemia. In that particular population with liver failure accompanied by sepsis, despite the use of MARS, no patients survived. They also reported significant bleeding side effects in this group, although they were using heparin to maintain PTT > 50 seconds to anti-coagulate the MARS system. They concluded that sepsis-related liver failure might not be an indication for MARS therapy.
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In our study, sepsis was not the primary cause of shock liver, but 2 patients in Group M (14%) and 3 patients in Group C (21%) were septic during the study. The Prior studies on the effectiveness of MARS in the acute-on-chronic liver failure population have found that treatment can improve hemodynamic status or have an effect on coagulation. 1, 12 We found an improvement of INR while on MARS ( Figures 1 & 2) ; however, we were not able to identify the hemodynamic improvement, maybe because hemodynamics were already supported by ECMO.
Our study supports that acute liver failure during ECMO can be supported with MARS and that once liver functions are normalized, no additional MARS are necessary. Additionally, the fact that five of the patients in Group M were implanted with ventricular assist devices points to recovery of end organ function, without any neurological deficits. Without recovery of liver function, these patients would not have been device candidates.
The decision to start MARS treatment was most often based upon increased total bilirubin.
However, we found the Group M had significantly higher liver enzymes as well. Group M also met criteria for acute liver failure sooner after ECMO initiation (3 ± 3 days) than Group C (6 ± 7 days). By day 3 after inclusion, only 70% (10/14) of the patients in Group C were alive, dropping to 36% (5/14)
survival by day 7. This is compared to 79% (11/14) survival to day 7 in Group M (p=0.02). This illustrates that medical therapy alone is not enough to stop the progression from acute liver failure to death in this patient population. All patients in the treatment group showed total bilirubin that trended downward by day 3, and continued downward until MARS was stopped (Figure 2 ) -suggesting that liver function recovered.
The main limitation of this study was small sample size, retrospective, single center experience. The decision to initiate MARS therapy was a clinical judgment base on the attending physician's assessment at the bedside and thus the two groups were not randomized. This study does not address discharge survival data. Because many surviving patients in Group M went on to receive permanent mechanical circulatory support devices, they required a more prolonged hospital stay. Survival to discharge data in that group would have many other confounding variables from those other forms of mechanical support devices as well as from the prolonged hospital stay. Going forward, research is needed to further refine the appropriate patient selection criteria and to initiate optimal treatment guidelines, as well as to determine if MARS therapy increases survival to discharge.
Study Highlights
At this time, the use of MARS liver dialysis for acute-on-chronic liver failure to prolong survival until transplantation has been accepted. 1,2 However, the research on expanding the use of MARS to other patient populations has demonstrated mixed results, regarding both safety and efficacy.
This study looked at a specific population -multiple-organ failure patients on ECMO with acute liver failure -in order to determine if MARS could improve survival to wean off ECMO. The results showed that without increasing complications, MARS could safely improve survival outcomes and accelerate liver recovery within this patient population. ECMO is widely used to support the patient while the heart and/or lungs recover, the results of this study indicate that the liver can recover in the same manner if the patient is supported with the MARS liver dialysis system.
Conclusion
The results of this study show that the MARS system for liver dialysis can safely and effectively be used for acute liver failure in cardiopulmonary failure patients who are being supported by ECMO in order to accelerate liver recovery. Survival benefit by MARS was clearly demonstrated, without any additional increase in complications.
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Figure 3:
Survival data.
